TODAY marks a significant milestone in the global fight against dengue fever as Malaysia launches its first-ever clinical trial for a locally produced antiviral solution.
Dengue fever, a growing health threat worldwide, has witnessed a ten-fold surge in reported cases from 2000 to 2019, according to the World Health Organisation (WHO), noting the urgent need for effective remedies.
This groundbreaking clinical trial is the result of over a decade of collaborative research between Universiti Malaya’s Tropical Infectious Diseases Research and Education Centre (TIDREC) and local bioscience company Herbitec Sdn Bhd. Partnering with award-winning Qualitas Health Group, the trial aims to translate laboratory discoveries into effective treatments to prevent severe dengue.
Universiti Malaya Research & Innovation deputy vice-chancellor Prof Ir Dr Kaharudin Dimyati noted the importance of collaboration in scientific research and healthcare innovation.
“I am particularly proud of the collaborative spirit that has fuelled the development of this clinical trial. The partnership between TIDREC, Herbitec Sdn Bhd and Qualitas exemplifies the power of collaboration in driving meaningful progress in scientific research and healthcare innovation.
“Together, we have pooled our expertise, resources, and collective determination to address this pressing public health challenge.”
Moreover, the trial aligns with WHO’s ambitious goal of achieving zero mortality from dengue by 2030, underlining its significance in global health initiatives.
Herbitec’s innovative product NODEN™ poised to revolutionise dengue treatment and Qualitas’ dedicated clinics for hosting the clinical trials showcase the fruitful collaboration between academia and the private sector.
Meanwhile, TIDREC executive director Prof Sazaly Abu Bakar pointed out the pivotal roles played by Herbitec and Qualitas.
“We are grateful to Herbitec, an indirect subsidiary of Tanco Holdings Bhd, and Qualitas for their pivotal roles in support of this initiative.
“Herbitec’s supply of NODEN™, an innovative product poised to revolutionise dengue treatment, and Qualitas hosting the clinical trials in their dedicated clinics, are exemplary of the mutually beneficial collaboration between academia and the private sector.
“This partnership would serve as an example of how research findings from the laboratory could make an impact on the real problems faced by the community.” – April 5, 2024
